Data gathered: January 21
AI Stock Analysis - Anavex Life Sciences (AVXL)
Analysis generated January 17, 2025. Powered by Chat GPT.
Anavex Life Sciences Corp. (AVXL) is a biopharmaceutical company primarily focused on the development of treatments for central nervous system (CNS) diseases. The company leverages its proprietary SIGMACEPTOR™ platform to develop potential treatments for diseases such as Alzheimer's disease, Parkinson's disease, Rett syndrome, and other CNS disorders. Anavex is known for its lead drug candidate, ANAVEX®2-73, which is progressing through various clinical trial stages. The company is based in New York City and operates within the competitive and fast-evolving pharmaceutical industry.
Stock Alerts - Anavex Life Sciences (AVXL)
 |
Anavex Life Sciences | January 17 Price is down by -5.8% in the last 24h. |
|
Anavex Life Sciences | January 16 Price is down by -5.2% in the last 24h. |
|
Anavex Life Sciences | January 15 Price is up by 6.3% in the last 24h. |
|
Anavex Life Sciences | January 13 Price is down by -6.6% in the last 24h. |
Alternative Data for Anavex Life Sciences
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 92 | Sign up | Sign up | Sign up |
| Webpage traffic | 28,000 | Sign up | Sign up | Sign up |
| Employee Rating | N/A | Sign up | Sign up | Sign up |
| Google Trends | 26 | Sign up | Sign up | Sign up |
| Patents | 40 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 139 | Sign up | Sign up | Sign up |
| Facebook Followers | 1,359 | Sign up | Sign up | Sign up |
| Reddit Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 54 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 22,266 | Sign up | Sign up | Sign up |
| Twitter Followers | 2,064 | Sign up | Sign up | Sign up |
| Twitter Mentions | 10 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| ESG | 43 | Sign up | Sign up | Sign up |
| Business Outlook | N/A | Sign up | Sign up | Sign up |
About Anavex Life Sciences
Anavex utilizes precision genetic medicine to treat severe and devastating neurological disorders and is focusing on rare diseases with no available therapy (Rett syndrome) as well as neurodegenerative diseases that are on the rise due to aging populations (Parkinson's Disease and Alzheimer's Disease) More about us.
| Price | $9.21 |
| Target Price | Sign up |
| Volume | 2,920,000 |
| Market Cap | $781M |
| Year Range | $3.7 - $13.46 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
Anavex Life Sciences : Corporate Presentation January 2025January 15 - Finnhub |
|
 |
Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer's DiseaseJanuary 15 - Investing.com |
 |
Anavex Life Sciences’ (AVXL) “Buy” Rating Reiterated at D. Boral CapitalJanuary 15 - ETF Daily News |
 |
Financial Contrast: Anavex Life Sciences (NASDAQ:AVXL) and Pluri (NASDAQ:PLUR)January 14 - ETF Daily News |
 |
Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer’s DiseaseJanuary 14 - Yahoo |
|
Watts Gwilliam & Co. LLC Purchases New Shares in Anavex Life Sciences Corp. (NASDAQ:AVXL)January 11 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '24 | 1.9M | 2.9M | -940,000 | -12M | -15M | -0.140 |
| Q1 '24 | 1.6M | 2.8M | -1.2M | -11M | -13M | -0.130 |
| Q4 '23 | 2.2M | 2.6M | -450,000 | -8.6M | -9.1M | -0.110 |
| Q3 '23 | 1.8M | 2.6M | -820,000 | -10M | -10M | -0.120 |
| Q2 '23 | 1.7M | 3.2M | -1.5M | -11M | -11M | -0.140 |
Insider Transactions View All
| Donhauser Peter D.O. filed to buy 5,000 shares at $3.6. June 17 '24 |
| Thomas Steffen filed to buy 5,000 shares at $4.5. May 17 '24 |
| MISSLING CHRISTOPHER U filed to sell 1,250,210 shares at $5.1. April 1 '24 |
| MISSLING CHRISTOPHER U filed to sell 1,018,210 shares at $8. June 30 '23 |
| Skarpelos Athanasios filed to sell 1,306,458 shares at $9.1. May 27 '22 |
Similar companies
Read more about Anavex Life Sciences (AVXL) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews & business outlook.
What is the Market Cap of Anavex Life Sciences?
The Market Cap of Anavex Life Sciences is $781M.
What is the current stock price of Anavex Life Sciences?
Currently, the price of one share of Anavex Life Sciences stock is $9.21.
How can I analyze the AVXL stock price chart for investment decisions?
The AVXL stock price chart above provides a comprehensive visual representation of Anavex Life Sciences' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Anavex Life Sciences shares. Our platform offers an up-to-date AVXL stock price chart, along with technical data analysis and alternative data insights.
Does AVXL offer dividends to its shareholders?
As of our latest update, Anavex Life Sciences (AVXL) does not offer dividends to its shareholders. Investors interested in Anavex Life Sciences should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Anavex Life Sciences?
Some of the similar stocks of Anavex Life Sciences are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and BridgeBio Pharma.
.